As of 2024-12-14, the EV/EBITDA ratio of Addex Therapeutics Ltd (ADXN.SW) is -1.66. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ADXN.SW's latest enterprise value is 7.76 mil CHF. ADXN.SW's TTM EBITDA according to its financial statements is -4.68 mil CHF. Dividing these 2 quantities gives us the above ADXN.SW EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.6x - 9.7x | 8.9x |
| Forward P/E multiples | 10.1x - 11.3x | 10.2x |
| Fair Price | (0.24) - (0.23) | (0.22) |
| Upside | -496.3% - -479.4% | -473.9% |
| Date | EV/EBITDA |
| 2024-12-13 | -1.66 |
| 2024-12-12 | -1.66 |
| 2024-12-11 | -1.66 |
| 2024-12-10 | -1.63 |
| 2024-12-09 | -1.59 |
| 2024-12-06 | -1.59 |
| 2024-12-05 | -1.45 |
| 2024-12-04 | -1.39 |
| 2024-12-03 | -1.75 |
| 2024-12-02 | -1.59 |
| 2024-11-29 | -1.74 |
| 2024-11-28 | -1.74 |
| 2024-11-27 | -1.77 |
| 2024-11-26 | -1.66 |
| 2024-11-25 | -1.52 |
| 2024-11-22 | -1.52 |
| 2024-11-21 | -1.52 |
| 2024-11-20 | -1.65 |
| 2024-11-19 | -1.61 |
| 2024-11-18 | -1.73 |
| 2024-11-15 | -1.62 |
| 2024-11-14 | -1.85 |
| 2024-11-13 | -1.74 |
| 2024-11-12 | -1.82 |
| 2024-11-11 | -2.37 |
| 2024-11-08 | -2.64 |
| 2024-11-07 | -2.64 |
| 2024-11-06 | -2.57 |
| 2024-11-05 | -2.45 |
| 2024-11-04 | -2.46 |
| 2024-11-01 | -2.57 |
| 2024-10-31 | -2.42 |
| 2024-10-30 | -2.34 |
| 2024-10-29 | -2.43 |
| 2024-10-28 | -2.39 |
| 2024-10-25 | -2.64 |
| 2024-10-24 | -2.67 |
| 2024-10-23 | -2.58 |
| 2024-10-22 | -2.60 |
| 2024-10-21 | -2.42 |
| 2024-10-18 | -2.22 |
| 2024-10-17 | -2.27 |
| 2024-10-16 | -2.25 |
| 2024-10-15 | -2.25 |
| 2024-10-14 | -2.06 |
| 2024-10-11 | -2.05 |
| 2024-10-10 | -2.18 |
| 2024-10-09 | -2.13 |
| 2024-10-08 | -2.13 |
| 2024-10-07 | -2.05 |